(Q38869197)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Taku Kato

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Kosuke Mizutani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Koji Kameyama

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Yasunori Fujita

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Keita Nakane

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Yusuke Kanimoto

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Hidetoshi Ehara

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Hiroyasu Ito

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Mitsuru Seishima

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Takashi Deguchi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Masafumi Ito

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

28 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

385.e15-20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

Prostate cancer epidemiology

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Characterising the castration-resistant prostate cancer population: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Short hairpin RNA-mediated MDR1 gene silencing increases apoptosis of human ovarian cancer cell line A2780/Taxol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Emerging novel therapies in the treatment of castrate-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Nanoways to overcome docetaxel resistance in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Exosomes as biomarker treasure chests for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Exosomal miRNAs as Biomarkers for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Exosomal microRNA: a diagnostic marker for lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Expression of the multidrug resistance gene in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Expression of a multidrug-resistance gene in human tumors and tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.04.019

10.1016/J.UROLONC.2015.04.019

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26027763%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference